

1 **New Admissions and Asymptomatic TB Cases fuel TB Epidemic in Prisons, a** 2 **Cross Sectional Survey in Tanzania**

3 Chacha David Mangu^{1†}, Petra Clowes^{1,6}, Jan van den Hombergh², Clement
4 Mwakabenga¹, Simeon Mwanyonga¹, Jane Ambindwile¹, Faith Kayombo¹, Monica
5 Minja¹, Samuel Kalluvya³, Lisa Gerwing-Adima^{3,4}, Christa Kasang⁴, Andreas Mueller⁴,
6 Edward Chilolo², Juma Angolwisye⁵, Dickson Nsajigwa⁵, Adili Kachima⁵, Deus Kamala⁶,
7 Beatrice Mutayobya⁶, Nyanda Elias Ntinginya¹, Michael Hoelscher^{7,8}, Elmar Saathoff^{7,8}
8 and Andrea Rachow^{7,8}

9 **Author's Affiliations**

- 10 1. National Institute for Medical Research, Mbeya Medical Research Center, Tanzania
- 11 2. PharmAccess International, Tanzania
- 12 3. Bugando Medical Centre, Mwanza, Tanzania
- 13 4. Medical Mission Institute, Wuerzburg, Germany
- 14 5. Ministry of Home Affairs; Prison Authority
- 15 6. National TB and Leprosy Program, Tanzania
- 16 7. Division of Infectious Diseases and Tropical Medicine, University Hospital, LMU Munich,
17 Germany
- 18 8. German Center for Infection Research (DZIF), Partner Site Munich, Germany

19 **†Corresponding Author**

20 **Email: cmangu@nimr-mmrc.org, +255713238757.**

21 **ABSTRACT**

22 **Background**

23 There is an increased risk for tuberculosis (TB) infection and disease progression in
24 prison settings. TB prevalence in prisons of high and middle/low income countries have
25 been measured to be between 5 and 50 -times higher than in the general population.

26 **Methods**

27 We performed TB active case finding in five central prisons, Keko, Segerea, Ukonga,
28 Butimba and Ruanda prison in Tanzania, using the Xpert MTB/RIF[®] assay on early
29 morning or spot sputum sample from inmates and new entries between April 2014 and
30 July 2015.

31 **Results**

32 Out of 13,868 prisoners tested, 13,763 had valid results. TB prevalence was 1.55%
33 (214/13,763); new admissions contributed to the majority (61.68%) of TB cases, but
34 prevalence was higher among inmates (1.75%) compared to new admissions (1.45%).
35 Ukonga, an urban prison which incarcerates long-term convicted inmates had the
36 highest prevalence of 4.02%. Male gender (OR=2.51, $p<0.001$), repeated incarcerations
37 (OR=2.85, $p<0.001$), history of TB treatment (OR=1.78, $p=0.002$), TB symptoms
38 (OR=2.78, $p=0.006$) and HIV infection (OR=2.86, $p=0.002$) were associated with
39 positive TB results.

40 **Conclusion**

41 New admissions could be the driving force of the TB epidemic in the penitentiary
42 system. However, prison environments remain a major risk factor for developing active
43 TB disease.

44

45 INTRODUCTION

46 Despite the efforts to reduce the global burden of TB, it has been one of the infectious
47 diseases causing substantial morbidity and mortality especially in Asia and Sub-
48 Saharan Africa^{1, 2}. It is estimated that 10.6 million people developed TB in 2021, 25% of
49 which occurred in Africa and caused 1.6 million deaths³. TB remains one of the major
50 causes of death among people living with HIV (PLHIV) causing 187,000 deaths in 2021
51 ³. TB cases are still under-reported; approximately 6.4 million cases (only 60.4% of
52 global estimated cases) were diagnosed and notified in 2021³. The majority of missed
53 TB cases most likely occur among people who lack free or direct access to health care
54 services such as prisoners and people incarcerated. Worldwide, it is estimated that
55 more than 9 million people are incarcerated at any point in time², and therefore faced
56 with a high risk environment for new TB infection and fastening the progression of latent
57 to active TB which, among others, is promoted by overcrowding, poor ventilation and
58 poor diet ^{4, 5}. Limited access to health care services results in late case detection and
59 delayed treatment initiation with potential poor adherence sustaining the ongoing TB
60 transmission in prisons ^{4, 5}.

61 Despite its highly endemic nature, prevalence of TB in prisons is largely unknown in
62 many countries. Systematic reviews showed incidences of 237.6 per 100,000 and
63 1,942.8 per 100,000 person-years in high and middle/low-income countries,
64 respectively^{6, 7}. Some studies have shown TB rates among inmates as high as 5 to 50
65 times greater than those of the general population across developed and developing
66 countries, respectively⁸. Active mass screening studies in Malawi, Ivory Coast, Zambia,
67 Botswana, Cameroon and Ethiopia, found TB prevalence among prisoners of about 7 to
68 more than 10 times higher than in the general population⁹⁻¹⁴. In Tanzania, a study at
69 Bugando Hospital, Mwanza, showed a proportion of 41% of smear-positive TB cases
70 among prisoners with presumptive TB referred for diagnosis¹⁵.

71
72 Despite the high TB prevalence and complexity that exists in the control of tuberculosis
73 in prisons, TB detection in most prisons still rely on symptomatic screening¹⁶, however
74 with the availability of approved molecular diagnostic tests, such as GeneXpert, which
75 are more sensitive, easy to perform and rapid, the systematic TB screening in a large

76 number of persons within a short time has been made possible¹⁹. The aim of this study
77 was to implement a screening strategy to actively detect TB in five central prisons in
78 Tanzania mainland using GeneXpert MTB/RIF and accurately measure the prevalence,
79 and understand the related risk factors of TB in prisons.

80

81 **METHODS**

82 ***Prisons and study groups***

83 The project was implemented in five central prisons in Tanzania; Keko, Segerea and
84 Ukonga Prisons within the highly populated business capital of the Indian Ocean coast
85 region Dar es Salaam; Butimba Prison in Northwest region, Mwanza; and Ruanda
86 Prison in the Southern Highland region, Mbeya. All prisons are located in urban settings
87 but admit prisoners from both urban and rural communities. According to the Tanzanian
88 prison authority, during the study period, these prisons housed an average of about
89 8,000 inmates in total and have a turnover of more than 15,000 new admissions and
90 discharges per year. TB screening was done among those who newly entered the
91 prison, were transferred in from another prison and inmates present in the prisons at the
92 beginning of the study.

93 ***Study procedures***

94 The project was implemented between April 2014 and June 2015. A screening
95 questionnaire administered by trained prison health staffs. was used to collect
96 demographic information, date of entry into prison, history of previous imprisonment,
97 number of inmates sharing a cell, presence of cell mate(s) treated for TB, TB
98 symptoms, self-reported past history of TB treatment, self-reported HIV status and use
99 of anti-retroviral treatment (ART). One spontaneously expectorate sputum sample was
100 collected from all study participants by a trained prison health facility staff, a nurse or
101 laboratory technician. TB diagnosis was done using the GeneXpert MTB/RIF[®] assay
102 (Xpert; Cepheid, Sunnyvale, California, US), which was stationed at each prison health
103 facility and operated by trained laboratory technicians who were also prison staff. In
104 case of a failed test (“error”, “invalid” or “no result”), Xpert testing was repeated on the
105 same sample or a newly collected sample if the sample was either inadequate,

106 discarded or of poor quality. For those consented for HIV testing, HIV diagnosis was
107 done according to the national guidelines using SD Bioline HIV-1/2 3.0 (Standard
108 Diagnostics, Inc. Yongin, South Korea), and confirmed by Alere Determine HIV-1/2
109 (Alere Inc. Massachusetts, USA) and Uni-Gold HIV-1/2 (Trinity Biotech, Co. Wicklow,
110 Ireland).

111 ***Ethical consideration***

112 The study obtained ethical clearance from the National Health Research and Ethics
113 Committee of the National Institute for Medical Research, Tanzania. It was also
114 approved by the Prison Headquarters as well as the National TB and Leprosy Program
115 in Tanzania.

116 Screening was voluntary; prisoners consented to participate and thumb printed the
117 informed consent form before study procedures were done. HIV diagnosis was done
118 through provider initiated testing and counseling (PITC) by a nurse counselor. Prisoners
119 who refused to test for HIV were not excluded from TB screening. Those diagnosed to
120 have TB or HIV were linked to care at the respective prison health facilities. Only
121 prisoners 18 years and above were included in the study.

122 ***Statistical analysis***

123 The main endpoint of this study was bacteriologically confirmed TB diagnosed by Xpert.
124 Univariate analysis was performed to describe the study population of screened
125 prisoners and the prevalence of TB in different strata of the independent variables.

126 A conceptual frame work (Fig. 1) was established to guide multivariable logistic
127 regression analysis in three levels. Variables with a p-value of <0.1 were retained and
128 used to adjust for variables in the subsequent level and retained in the last model; and
129 variables in the last model with the p-value of <0.05 were considered significant risk
130 factors for TB in prisons. Variables considered distal to the outcome and those proximal
131 to the outcome were in the first and last levels respectively. Number of cell mates was
132 forced into the final model due to its importance in assessing overcrowding within prison
133 cells. Robust standard errors were used in logistic regression to account for correlation
134 within prisons. The Wald test was used to assess significance of the contribution of

135 each variable to the model. Data analysis was performed using Stata/SE version 14
136 (Stata Corporation, College Station, Texas, US).

137 **Figure 1. Hypothesized conceptual framework to guide model building for**
138 **multivariate analysis**

139

140 **RESULTS**

141 A total of 16,132 prisoners from 5 central prisons agreed to participate in the study and
142 completed the questionnaire. Of these, 13,868 prisoners were screened using Xpert, of
143 which 105 had either an invalid or erroneous final result. Thus, the final analysis
144 included 13,763 prisoners with valid Xpert result.

145 ***Baseline characteristics***

146 Of the 13,763 prisoners, majority (96.3%, n=13,248) were male. The median age of
147 screened prisoners was 30 years (IQR 24–36 years) while 64.7% were younger than 35
148 years. A total of 9,077 (66.0%) prisoners screened were new admissions and 12,035
149 (87.4%) were in prison for the first time. The median duration of incarceration was 1.5
150 months at the time point of study participation and sharing a cell with more than 10
151 inmates was common (93.8%, n=12,911). More than half (51.6%, n=7,106) had
152 unknown HIV status, and 6.1% (n=833) were HIV positive (Table 1).

153

154 TABLE 1. Characteristics of the study population and TB cases

Characteristics	Categories	Total (col%) [N=13,763]	Prisoners with tuberculosis (col%) [N=214]	Prevalence of Tuberculosis in %	P-value*
Sex	Female	515 (3.7)	4 (1.9)	0.78	0.150
	Male	13,248 (96.3)	210 (98.1)	1.59	
Age in years	<25	3,731 (27.1)	35 (16.4)	0.94	0.004
	25-34	5,177 (37.6)	87 (40.7)	1.68	
	35-44	3,030 (22.0)	58 (27.1)	1.91	
	>45	1,825 (13.3)	34 (15.9)	1.86	
Prisoner Status	New Admission	9,077 (66.0)	132 (61.7)	1.45	0.184
	Inmate	4,686 (34.0)	82 (38.3)	1.75	
Duration of Incarceration	<6 months	8,643 (62.8)	114 (53.3)	1.32	0.023
	6-24 months	1,703 (12.4)	37 (17.3)	2.17	
	24-60 months	1,246 (9.1)	21 (9.8)	1.69	
	>60 months	2,171 (15.8)	42 (19.6)	1.93	
Number of Incarcerations	1	12,035 (87.4)	163 (76.2)	1.35	<0.001
	2-3	1,573 (11.4)	41 (19.2)	2.61	
	≥4	155 (1.1)	10 (4.7)	6.45	
Number of Cell Mates	<5	47 (0.3)	2 (0.9)	4.26	0.195
	6-10	805 (5.9)	9 (4.2)	1.12	
	>10	2,911 (93.8)	203 (94.9)	1.57	
Known TB contact from Cell Mate	No	13,713 (99.6)	212 (99.1)	1.55	0.162
	Yes	50 (0.4)	2 (0.9)	4.00	
Previously treated for TB	Yes	666 (4.8)	33 (15.4)	4.95	<0.001
	No	13,097 (95.2)	181 (84.6)	1.38	
Reported one or more TB symptoms	Yes	2,261 (16.4)	92 (43.0)	4.07	<0.001
	No	11,502 (83.6)	122 (57.0)	1.06	
HIV Status	Negative	5,824 (42.3)	85 (39.7)	1.46	<0.001
	Positive	833 (6.1)	40 (18.7)	4.80	
	Not Known	7,106 (51.6)	89 (41.6)	1.25	
Prison ID	Ruanda	4520 (32.8)	42 (19.6)	0.98	<0.001
	Butimba	4328 (31.5)	48 (22.4)	1.12	
	Ukonga	828 (6.0)	32 (15.0)	4.02	
	Keko	1921 (14.0)	26 (12.2)	1.37	
	Segerea	2166 (15.7)	66 (30.8)	0.03	

155 *chi squared test p-value for difference in TB-prevalence between strata

156 ***Risk factors associated with TB diagnosis***

157 In multivariable analysis, males had more than two times the odds for TB infection than
158 females (Odds Ratio [OR] = 2.51, 95% confidence interval [CI] = 1.54 to 4.08, p-value
159 [p] = <0.001). Age did not appear to be an important independent risk factor for active
160 TB. The OR significantly increased with the frequency of incarcerations to nearly three
161 times higher odd for active TB in prisoners who have been in prison four or more times
162 (OR=2.85 CI=1.78 to 4.55, p<0.001). Previous history of TB treatment was associated
163 with current active TB disease (OR=1.78, CI=1.24 to 2.55, p=0.002). Participants with
164 TB symptoms were three times more likely to test positive for TB than those without
165 symptoms (OR=2.78, CI=1.35 to 5.74, p<0.006) and HIV positive prisoners also had
166 significantly higher odds of TB than HIV-negative prisoners (OR=2.86, CI=1.49 to 5.52,
167 p=0.002). Being incarcerated in prisons located in the business capital, Ukonga prison
168 (which admits convicted offenders) or Segerea prison (which admits new remandees)
169 was associated with a two times higher OR for having TB (OR= 2.15, CI 1.63 to 2.83,
170 p<0.001 and OR=2.10, CI 1.75 to 2.52, p<0.001 respectively). Sharing a cell with more
171 than 10 people was not associated with TB infection (Table 2).

172 TABLE 2. Association of various factors with TB disease (N = 13,763; n= 214 (1.555%): Uni-
 173 and multi-variable logistic regression results; using robust variance estimates adjusted for
 174 clustering by PrisonID.

Covariate	N	n	%	Univariable			Multivariable		
				OR	95% CI	p-value	OR	95% CI	p-value
Sex									
Female*	515	4	0.777	1.00	-	-	1.00	-	-
Male	13,248	210	1.585	2.06	(1.03 to 4.11)	0.041	2.51	(1.54 to 4.08)	<0.001
agegroup									
< 25 yrs*	3,731	35	0.938	1.00	-	-	1.00	-	-
25 - <35 yrs	5,177	87	1.681	1.80	(1.49 to 2.19)	<0.001	1.31	(0.97 to 1.78)	0.083
35 - <45 yrs	3,030	58	1.914	2.06	(1.33 to 3.20)	0.001	1.28	(0.75 to 2.21)	0.365
>=45 yrs	1,825	34	1.863	2.00	(0.98 to 4.11)	0.058	1.30	(0.70 to 2.42)	0.399
Number of Incarcerations									
1*	12,035	163	1.354	1.00	-	-	1.00	-	-
2-3	1,573	41	2.606	1.95	(1.15 to 3.31)	0.013	1.57	(1.17 to 2.09)	0.002
>4	155	10	6.452	5.02	(2.57 to 9.81)	<0.001	2.85	(1.78 to 4.55)	<0.001
Duration of Incarceration									
<=6 months*	8,643	114	1.319	1.00	-	-	1.00	-	-
6 - 24 months	1,703	37	2.173	1.66	(1.35 to 2.05)	<0.001	1.31	(1.07 to 1.62)	0.010
24 - 60 months	1,246	21	1.685	1.28	(0.79 to 2.09)	0.318	0.87	(0.61 to 1.22)	0.414
>60 months	2,171	42	1.935	1.48	(0.72 to 3.05)	0.292	0.95	(0.77 to 1.18)	0.669
HIV Result									
Negative*	5,824	85	1.459	1.00	-	-	1.00	-	-
Positive	833	40	4.802	3.41	(1.68 to 6.89)	<0.001	2.86	(1.49 to 5.52)	0.002
Unknown	7,106	89	1.252	0.86	(0.67 to 1.09)	0.214	1.18	(0.86 to 1.61)	0.314
History of TB Treatment									
No*	13,097	181	1.382	1.00	-	-	1.00	-	-
Yes	666	33	4.955	3.72	(2.87 to 4.82)	<0.001	1.78	(1.24 to 2.55)	0.002
Number of Cell Mates									
<10*	852	11	1.291	1.00	-	-	1.00	-	-
>10	12,911	203	1.572	1.22	(0.89 to 1.68)	0.216	0.93	(0.74 to 1.18)	0.570
Any TB Symptoms									
No*	11,502	122	1.061	1.00	-	-	1.00	-	-
Yes	2,261	92	4.069	3.96	(2.13 to 7.35)	<0.001	2.78	(1.35 to 5.74)	0.006
PrisonID									
Ruanda*	4,520	42	0.929	1.00	-	-	1.00	-	-
Butimba	4,328	48	1.109	1.20	(1.20 to 1.20)	<0.001	1.10	(1.02 to 1.20)	0.019
Ukonga	828	32	3.865	4.29	(4.29 to 4.29)	<0.001	2.15	(1.63 to 2.83)	<0.001
Keko	1,921	26	1.353	1.46	(1.46 to 1.46)	<0.001	1.08	(1.01 to 1.15)	0.027
Segera	2,166	66	3.047	3.35	(3.35 to 3.35)	<0.001	2.10	(1.75 to 2.52)	<0.001

N = number of observations; n= number of positives; %= percent positive; 95% CI = 95% confidence interval
 * reference stratum

175 **DISCUSSION**

176 Our findings show a high TB burden in Tanzania prisons. The prevalence of
177 bacteriologically confirmed TB of 1.55% (1,550 cases/100,000 population) is more than
178 5 times higher than the prevalence in the general population of 295 per 100,000¹⁸.

179 Our study contributes important findings over the containment of asymptomatic TB
180 cases in prison settings. Sustained and prolonged exposure to TB bacilli could be
181 maintained in prison walls by asymptomatic cases and can potentially propagate TB
182 transmission among inmates if conventional symptomatic TB screening is the only
183 screening method relied on since studies have shown that asymptomatic TB cases
184 have the ability to infect others^{16,19-20}. For this reason robust and effective approaches
185 using effective diagnostic tools for TB screening in prisoners are required. Nonetheless,
186 TB symptoms remain a major predictor of TB disease as shown by a TB high
187 prevalence in prisoners with symptoms compared to those without (4.07% vs 1.06%
188 respectively). Therefore an effective screening intervention is the one that apply mixed
189 methods that detect both symptomatic and asymptomatic TB.

190 Despite high TB prevalence among inmates, the fact that 61% of detected TB cases in
191 this study were among new admissions suggests that new admissions bring TB into the
192 prison facilities and therefore contribute significantly to the TB epidemic in prisons.
193 These findings also observed in other studies^{21, 22} in countries with high TB burden
194 suggests two possible explanations; firstly, many of those who commit offenses and end
195 up in a penal institution come from a background of high risk for TB infection and
196 therefore bring with them an increased risk for TB infection into prison and actively
197 contribute to the high prevalence of TB in prisons⁵. And secondly, it is highly likely that
198 specific conditions in prisons lead to a higher risk of TB infection and accelerate latent
199 TB infections to progress to active disease within a short duration of time. Many TB
200 control strategies in prisons focus on already incarcerated inmates while little or no
201 attention is given to new admissions. Findings from our study suggest that equal weight
202 has to be given to both groups of prisoners. Constant screening at prison-entry aims at
203 detecting untreated admissions and thereby reduce introduction of new TB cases into

204 prison while mass and contact screening should aim at detecting the circulating TB
205 within the prison walls²³.

206 Our findings do not suggest overcrowding to be a risk factor for TB disease in prison;
207 however, this might be due to the possibility that the disaggregation by number of
208 inmates per cell during data collection was not specific enough and hence it probably
209 obscures the association. Similarly, having a known TB contact within the cells was not
210 associated with TB infection in our study, however, this finding could be due to the fact
211 that more than 50% of the identified TB cases were new entries who didn't have
212 prolonged contact with other inmates during the time of screening. Yet, screening of
213 individuals who have contact with index cases should still continue as recommended
214 because it is effective in increasing case detection^{23, 24, 25}. HIV remains an important
215 single predictor of TB infection in prison settings as it is well known to fuel the TB
216 epidemic²⁶. Notably, effective control of TB infection also requires appropriate
217 interventions against HIV infection.

218

219 **CONCLUSION AND RECOMMENDATIONS**

220 Our study showed a high TB burden in Tanzanian prisons. The majority of positive TB
221 tests was among symptomatic prisoners, new entries and inmates who stayed only for a
222 short time in prison. Other TB risk factors were not prison-associated. Prisoners remain
223 a high risk population with great mobility due to perpetuating referrals between prisons
224 and interactions with the outside communities; our results suggest that TB screening
225 measures within prisons need to be sensitive, robust and with a fast enough turn-over
226 time to combat TB in prisoners and consequently interrupt TB transmission not only in
227 prisons but also in the surrounding communities.

228 TB screening on admission or exit for both remandees and inmates using WHO
229 recommended PCR based rapid diagnostics such as GeneXpert was not a routine
230 practice in Tanzania prisons at the time of this study. However, because of the findings
231 of this study, active TB screening on all prison entry points have been implemented in

232 Tanzania ever since. Future research is needed to assess the impact of the
233 implementation of WHO approved rapid TB diagnostic tools in prison settings.

234

235 **Acknowledgements**

236 We acknowledge the effort from all collaborating institutions implementing the study,
237 NIMR-Mbeya Centre, Tanzania (project lead); PharmAccess International, Tanzania;
238 Medical Mission Institute of Wuerzburg, Germany; Bugando Referral Hospital,
239 Tanzania; Division of Infectious Diseases and Tropical Medicine, University of Munich
240 (LMU) Germany (grant holder). We thank the Tanzania Prison Authority Headquarter,
241 and the National TB and Leprosy Program for facilitating study activities. To all the
242 prison health staffs for your dedication and prisoners for your participation, we thank
243 you.

244

245 **Conflicts of interests**

246 Authors declare no conflict of interest.

247 **Funding**

248 The project was funded by the WHO, STOP TB Partnership through the TB REACH
249 funding initiative.

250 **Authors Contribution**

251 CDM, PC, MH, AR designed the study, applied for grant, supervised study
252 implementation, and reviewed the manuscript.

253 CDM, ES performed data analysis.

254 JH, CM, JA, FK, MM, SK, LG, CK, AM, DK, & NE reviewed the study design,
255 coordinated and supervised study implementation, and reviewed the manuscript;

256 CDM wrote the manuscript

257 **References**

- 258 1. Dye C. Global Epidemiology of tuberculosis. *Lancet* 2006; 367:938-40.
- 259 2. Dye C, Lönnroth K, Jaramillo E, Williamsa BG, and Raviglionea M. Trends in
260 tuberculosis incidence and their determinants in 134 countries. *Bulletin of the*
261 *World Health Organization*. 2009; 87(683-691):
- 262 3. WORLD HEALTH ORGANIZATION *Global Tuberculosis Report 2022*. ISBN 978-
263 92-4-001313-1. WHO Press, Geneva, 2020. 1-208.
- 264 4. Dara M, Acosta CD, Melchers NV, Al-Darraji HA, Chorgoliani D, Reyes H, et al.
265 Tuberculosis control in prisons: current situation and research gaps. *Int J Infect*
266 *Dis*. 2015 Mar; 32:111-7.
- 267 5. Reyes HN. Pitfalls of TB Management in Prisons, Revisited. *International Journal*
268 *of Prisoner Health*, 2007; 3(1).43-67
- 269 6. Baussano I, Williams BG, Nunn P, Beggiato M, Fedeli U, Scano F. Tuberculosis
270 Incidence in Prisons: A Systematic Review. *PLoS Med* 2010; 7(12): e1000381.
271 Available from:
272 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000381>
- 273 7. WOLRD HEALTH ORGANIZATION. Literature Review on Tuberculosis in
274 Prisons. Geneva, WHO 2008: 1-16
- 275 8. THE PLoS MEDICINE EDITORS. The Health Crisis of Tuberculosis in Prisons
276 Extends beyond the Prison Walls. *PLoS Med* 2010; 7(12): Available from:
277 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1000383>
- 278 9. Nyangulu DS, Harries AD, Kangombe C, Yadidi AE, Chokani K, Culliana T, et al.
279 Tuberculosis in a prison population in Malawi. *The Lancet*. 1997; 350(9087).
280 1284-7.
- 281 10. Koffi N, Ngom AK, Aka-Danguy E, Seka A, Akoto A, Fadiga D. Smear positive
282 pulmonary tuberculosis in a prison setting: Experience in the penal camp of
283 Bouake, Ivory Coast. *Int J Tuberc Lung Dis*. 1997; 1(3).250-3.
- 284 11. Habeenzu C, Mitarai S, Lubasi D, Mudenda V, Katenga T, Mwansa J, et al.
285 Tuberculosis and multidrug resistance in Zambian prisons, 2000-2001. *Int J*
286 *Tuberc Lung Dis*. 2007 Nov; 11(11):1216-20

- 287 12. Noeske J, Kauban C, Amougou G, Pibello A, Poillot R. Pulmonary tuberculosis in
288 the Central Prison of Douala, Cameroon. *East Afr Med J.* 2006; 83(1):25-30
- 289 13. Abebe DS, Bjune G, Ameni G, Biffa D, Abebe F. Prevalence of pulmonary
290 tuberculosis and associated risk factors in Eastern Ethiopian prisons. *Int J*
291 *Tuberc Lung Dis.* 2011; 15(5):668-73.
- 292 14. O'Grady J, Hoelscher M, Atun R, Bates M, Mwaba P, Kapata N, et al.
293 Tuberculosis in prisons in sub-Saharan Africa the need for improved health
294 services surveillance and control. *Elsevier* 2010; 10(12):1-6.
- 295 15. Rutta E, Mutasigwa D, Ngallba S, Mwansasu A. Tuberculosis in a prison
296 population in Mwanza, Tanzania. *Int J Tuberc Lung Dis.* 2001; 5(8):703-6.
- 297 16. Reid ES, Topp SE, Turnbull ER, Hatwiinda S, Harris JB, Maggard KR, et al.
298 Tuberculosis and HIV Control in Sub-Saharan African Prisons: "Thinking Outside
299 the Prison Cell". *J Infect Dis.* 2012; 205(Suppl 2): S265-73
- 300 17. WORLD HEALTH ORGANIZATION. Consolidated guidelines on tuberculosis.
301 Module 3: diagnosis-rapid diagnostics for tuberculosis detection, 2021 update.
302 Geneva: World Health Organization; 2021. 1-137
- 303 18. UNITED REPUBLIC OF TANZANIA, MINISTRY OF HEALTH AND SOCIAL
304 WELFARE. *The First National Tuberculosis Prevalence Survey in the United*
305 *Republic of Tanzania, Final Report.* Dar Es Salaam, [publisher unknown], 2013.
306 1-156
- 307 19. Shaw JB, Ynn-Williams N. Infectivity of pulmonary tuberculosis in relation to
308 sputum status. *Am. Rev. Tuberc.* 1954; **69**:724-32.
- 309 20. Tostmann A, Kik VS, Lakisvaart AN, Sebek MM, Verver S, Boeree JM, et al.
310 Tuberculosis Transmission by Patients with Smear-Negative Pulmonary
311 Tuberculosis in a Large Cohort in The Netherlands. *Clin Infect Dis.* 2008; 47
312 (9):1135-42.
- 313 21. Moges B, Amare B, Asfaw F, Tesfaye W, Tiruneh M, Belyhun Y, et al.
314 Prevalence of smear positive pulmonary tuberculosis among prisoners in North
315 Gonder Zone Prison, Northwest Ethiopia. *BMC Infectious Disease* 2012;
316 12(352):1471-2334.
- 317 22. Winetsky DE, Almukhamedov O, Pulatov D, Vezhinina N, Dooronbekova A,
318 Zhussupov B. Prevalence, Risk Factors and Social Context of Active Pulmonary

- 319 Tuberculosis among Prison Inmates in Tajikistan PLoS Med 2014; 9(1): e86046.
320 Available from:
321 <https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0086046>
- 322 23. Dara M, Grzemska M, Kimerling ME, Reyes H and Zagorskiy A. Guidelines for
323 Control of Tuberculosis in Prisons. [Internet] [place unknown] TB CAP 2009.
324 [Cited: 24 June 2014]. 4-151. Available from:
325 [https://www.challengeb.org/publications/tools/ua/Guidelines_for_control_of_TB_i](https://www.challengeb.org/publications/tools/ua/Guidelines_for_control_of_TB_in_prisons.pdf)
326 [n_prisons.pdf](https://www.challengeb.org/publications/tools/ua/Guidelines_for_control_of_TB_in_prisons.pdf)
- 327 24. WORLD HEALTH ORGANISATION. WHO consolidated guidelines on
328 tuberculosis. Module 2: screening – systematic screening for tuberculosis
329 disease. Geneva: World Health Organization; 2021.
- 330 25. WORLD HEALTH ORGANISATION. Guidelines for the control of tuberculosis in
331 prisons. Geneva: World Health Organization; 1998.
- 332 26. Corbett EL, Bandason T, Cheung YB, Munyati S, Godfrey-Fausset P.
333 Epidemiology of Tuberculosis in a High HIV Prevalence Population Provided with
334 Enhanced Diagnosis of Symptomatic Disease. PLoS Med 2007; 4(1): e22.
335 Available from:
336 <https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.0040022>

Demographic Factors

1. Age
2. Sex

Prison Environment and factors

1. Duration of Incarceration
2. Number of Incarcerations
3. Number of inmates sharing a cell
4. Specific Prison

Clinical factors

1. Known TB Contact from cell mate
2. HIV Status
3. Previous history of TB treatment
4. TB Symptoms

Tuberculosis
Disease

Figure 1

